pentobarbital will lower the level or outcome of pimavanserin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on. Stay away from coadministration if possible. Check for reduced pimavanserin efficacy. An increase in pimavanserin dosage can be required.
pentobarbital will lessen the extent or outcome of etoposide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will minimize the extent or outcome of cobimetinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration. Robust or average CYP3A inducers could lessen cobimetinib systemic publicity by >eighty% and minimize its efficacy.
Contraindicated (1)pentobarbital will decrease the level or outcome of cariprazine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is liable for the formation and elimination of cariprazine's active metabolites.
pentobarbital will reduce the level or outcome of zaleplon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Not known.
pentobarbital will decrease the level or impact of estradiol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will reduce the extent or impact of tamoxifen by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
Avoid coadministration of ganaxolone with moderate or solid CYP3A4 inducers. If coadministration unavoidable, take into consideration expanding ganaxolone dose; nonetheless, don't exceed highest daily dose for pounds.
pentobarbital will decrease the level or result of theophylline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will minimize the level or influence of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will lower the extent or result of tamoxifen by affecting hepatic enzyme CYP2C9/10 metabolism. Use Warning/Observe.
pentobarbital will minimize the level or result of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead on to some lessen in fentanyl plasma concentrations, lack of efficacy or, maybe, growth of a withdrawal syndrome in get more info the patient who may have formulated Bodily dependence to fentanyl.
buprenorphine subdermal implant and pentobarbital both boost sedation. Keep away from or Use Alternate Drug. Limit use to individuals for whom choice remedy selections are insufficient
Monoamine oxidase inhibitors (MAOI) may inhibit barbiturate metabolism and lengthen barbiturate effects; keep track of closely